ISSN: 0973-7510

E-ISSN: 2581-690X

Research Article | Open Access
P.M. Anooja and Anu P. John
Department of Microbiology, Government Medical College, Kerala University of Health Sciences (KUHS), Thrissur, Kerala, India.
J Pure Appl Microbiol. 2021;15(4):2117-2124 | Article Number: 7186
https://doi.org/10.22207/JPAM.15.4.34 | © The Author(s). 2021
Received: 17/07/2021 | Accepted: 01/09/2021 | Published: 04/10/2021
Abstract

Pseudomonas aeruginosa is inherently resistant to many drugs. It is now an emerging opportunistic pathogen of clinical relevance. The emergence of carbapenemases is another major concern. Initiation of appropriate therapy is of paramount importance thus highlighting the need of active surveillance for newer emerging resistance trends for better infection control. To study the resistance pattern of P. aeruginosa isolates obtained from lab specimens and to determine the production of ESBL and Carbapenemase among them. A hospital-based cross-sectional study was carried out in the Department of Microbiology, Government medical college Thrissur, among P. aeruginosa isolates obtained from lab specimens, from January 2018 – December 2018. 162 isolates were studied. Antimicrobial susceptibility testing was done by Kirby – Bauer disc diffusion method, extended-spectrum beta-lactamase (ESBL) production was confirmed by and phenotypic confirmatory disc diffusion test. Carbapenemase detection was done using the modified carbapenemase inactivation (mCIM) method. The obtained data was analysed. Among 162 isolates 83% were non-multidrug-resistant (MDR) strains and 17% were MDR strains. 22% of ceftazidime resistant isolates were ESBL producers. 6.2% isolates were resistant to imipenem. Among the imipenem resistant isolates, Carbapenemase production was seen in 30% isolates by mCIM test. According to our study, the most effective antibiotic against P. aeruginosa were imipenem and cefoperazone/sulbactam showing resistance in 6.3% and 6.9% isolates respectively. The diversity of antibiotic resistance mechanisms and the emergence of carbapenem resistance is a threat that limits treatment choices. This suggests the need for ongoing antimicrobial susceptibility studies in the future.

Keywords

Pseudomonas aeruginosa, multidrug resistance, ESBL, carbapenemase, mCIM

Article Metrics

Article View: 662

Share This Article

© The Author(s) 2021. Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License which permits unrestricted use, sharing, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.